The receptor expression pattern in ductal carcinoma in situ predicts recurrence

Julie Kepple, Ronda S. Henry-Tillman, V. Suzanne Klimberg, Rakshanda Layeeque, Eric Siegel, Kent Westbrook, Soheila Korourian

Research output: Contribution to journalArticlepeer-review

37 Scopus citations


Background: The treatment of ductal carcinoma in situ (DCIS) is based on size and pathologic morphology. We hypothesized that as with invasive breast cancer, receptor expression in DCIS is important for predicting recurrence. Methods: Retrospective review from 1990 through 2002 identified 94 DCIS patients who had documented estrogen receptor (ER), progesterone receptor (PR), p53, Her-2/neu (HER), tumor characteristics, type of surgery, use of radiation or tamoxifen, and site of recurrence. Results: Median age and tumor size was 57.5 years and 2.0 cm, respectively. Median follow-up was 4 years. Overall recurrence rate was 6%. The ER-positive/PR-negative/HER-positive receptor pattern represented 50% (3 of 6) of total recurrences (P = .01). The length of disease-free-survival in the ER-positive/PR-negative/HER-positive receptor pattern was significantly shorter than in the rest of the patients (P = .0011). Comments: Receptor expression may be important in DCIS for predicting recurrence. HER positivity, even with ER positivity, is significantly associated with a higher risk of recurrence.

Original languageEnglish (US)
Pages (from-to)68-71
Number of pages4
JournalAmerican Journal of Surgery
Issue number1
StatePublished - Jul 2006
Externally publishedYes


  • Breast cancer
  • Ductal carcinoma in situ
  • Estrogen receptor
  • HER 2 neu receptor
  • Recurrence
  • Tamoxifen

ASJC Scopus subject areas

  • Surgery


Dive into the research topics of 'The receptor expression pattern in ductal carcinoma in situ predicts recurrence'. Together they form a unique fingerprint.

Cite this